223 related articles for article (PubMed ID: 1385137)
1. Changes in prostate-specific antigen and prostatic acid phosphatase concentration following prostatic examination in benign prostatic hypertrophy and prostate cancer patients.
Romics I; Galamb L
Eur Urol; 1992; 21 Suppl 1():83-6. PubMed ID: 1385137
[TBL] [Abstract][Full Text] [Related]
2. Relationship between prostatic acid phosphatase and prostate-specific antigen serum levels and prostatic volume in benign prostate hyperplasia. Pitfall on tumor markers assessment in primary prostatic cancer?
Omacini S; Mione R; Barichello M; Santucci Delli Ponti U; Bolgan A; Contemori GP; Petracco S; Capitanio G; Donisi PM; Gion M
Eur Urol; 1992; 21 Suppl 1():108-10. PubMed ID: 1385128
[TBL] [Abstract][Full Text] [Related]
3. The effect of manipulation of the prostate gland on serum prostate-specific acid phosphatase measured by radioimmunoassay.
Vihko P; Lukkarinen O; Kontturi M; Vihko R
Invest Urol; 1981 Mar; 18(5):334-6. PubMed ID: 6162819
[TBL] [Abstract][Full Text] [Related]
4. [Effects of prostatic massage on serum levels of prostatic acid phosphatase and specific antigen].
Sahin A; Ozen H; Balbay D; Bircan K; Koray Z; Karaagaoglu E; Remzi D
Bull Cancer; 1992; 79(11):1097-100. PubMed ID: 1284587
[TBL] [Abstract][Full Text] [Related]
5. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
[TBL] [Abstract][Full Text] [Related]
6. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
[TBL] [Abstract][Full Text] [Related]
7. The effect of digital rectal examination, flexible cystoscopy and prostatic biopsy on free and total prostate specific antigen, and the free-to-total prostate specific antigen ratio in clinical practice.
Collins GN; Martin PJ; Wynn-Davies A; Brooman PJ; O'Reilly PH
J Urol; 1997 May; 157(5):1744-7. PubMed ID: 9112518
[TBL] [Abstract][Full Text] [Related]
8. Correlation of prostate-specific antigen and prostate-specific antigen density with outcome of prostate biopsy.
Bare R; Hart L; McCullough DL
Urology; 1994 Feb; 43(2):191-6. PubMed ID: 7509526
[TBL] [Abstract][Full Text] [Related]
9. Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy.
Marrink J; Oosterom R; Bonfrer HM; Schröder FH; Mensink HJ
Eur J Cancer; 1993; 29A(4):570-1. PubMed ID: 7679580
[TBL] [Abstract][Full Text] [Related]
10. Prostate specific antigen and prostate specific antigen density. Roles in patient evaluation and management.
Benson MC; Olsson CA
Cancer; 1994 Sep; 74(6):1667-73. PubMed ID: 7521783
[TBL] [Abstract][Full Text] [Related]
11. Serum PSA and PAP measurements discriminating patients with prostate carcinoma from patients with nodular hyperplasia.
Shih WJ; Collins J; Mitchell B; Wierzbinski B
J Natl Med Assoc; 1994 Sep; 86(9):667-70. PubMed ID: 7525979
[TBL] [Abstract][Full Text] [Related]
12. [Significance of various examination methods in the management of prostatic cancer].
Romics I; Kaldenbach R; Bach D
Orv Hetil; 1994 May; 135(22):1191-4. PubMed ID: 7517027
[TBL] [Abstract][Full Text] [Related]
13. [Determination of tumor markers in the diagnosis of prostatic cancer].
Casas Terrón E; Mari Ruiz M; Molina Andreu E
Arch Esp Urol; 1993 Mar; 46(2):99-103. PubMed ID: 7684585
[TBL] [Abstract][Full Text] [Related]
14. [Comment on Grond, A., M. Ostermann-Myrau: Benign and malignant diseases of the prostate].
Grond A
Versicherungsmedizin; 1995 Apr; 47(2):66-7. PubMed ID: 7539193
[No Abstract] [Full Text] [Related]
15. Prostate specific antigen density: a method for differentiating prostate carcinoma from benign prostatic hypertrophy demonstrates ethnic variation.
Martin AA; Clejan S
J La State Med Soc; 1994 Apr; 146(4):163-71. PubMed ID: 7516401
[No Abstract] [Full Text] [Related]
16. [BIOMARKERS OF EARLY AND DIFFERENTIAL DIAGNOSIS OF PROSTATIC CANCER].
Grygorenko VM; Danylets RO; Vikarchuk MV; Gorbahn LV; Klepko AV
Klin Khir; 2017; (1):54-7. PubMed ID: 30272918
[TBL] [Abstract][Full Text] [Related]
17. Effect of digital rectal examination on plasma prostate-specific antigen (PSA).
Dutkiewicz S; Stepień K; Witeska A
Int Urol Nephrol; 1996; 28(2):211-4. PubMed ID: 8836791
[TBL] [Abstract][Full Text] [Related]
18. Clinical behavior of prostatic specific antigen and prostatic acid phosphatase: a comparative study.
Morote Robles J; Ruibal Morell A; Palou Redorta J; de Torres Mateos JA; Soler Roselló A
Eur Urol; 1988; 14(5):360-6. PubMed ID: 2458936
[TBL] [Abstract][Full Text] [Related]
19. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H
Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607
[TBL] [Abstract][Full Text] [Related]
20. [Usefulness of PSA density (PSAD) in the differential diagnosis between prostatic adenocarcinoma and benign ++ prostatic hypertrophy].
Tiranti D; Annoscia S; Montefiore F; Boccafoschi C
Arch Ital Urol Androl; 1994 Sep; 66(4 Suppl):59-63. PubMed ID: 7534168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
